Intera Oncology
Intera Oncology, a specialist in colorectal and cholangiocarcinoma treatments, acquires and improves oncology drugs.
Founded
2019Intera Oncology, a specialist in colorectal and cholangiocarcinoma treatments, acquires and improves oncology drugs.
Intera Oncology, founded with a mission to enhance the survival rates of colorectal cancer and cholangiocarcinoma patients, specializes in acquiring and improving oncology drugs. The company focuses on innovative drug delivery systems, particularly the Hepatic Arterial Infusion (HAI) therapy, which directly targets liver tumors. Their flagship product, the Intera 3000 HAI Pump, exemplifies their commitment to providing advanced treatment options for patients battling these aggressive cancers.
Notable figures associated with Intera Oncology include key leaders from the medical and pharmaceutical industries, although specific names are not detailed. The company has achieved significant milestones by acquiring drug delivery products from Johnson & Johnson, demonstrating their capability to handle and enhance complex oncology treatments. Intera Oncology's impact is evident in its contribution to extending patient survival and improving the quality of life for those affected by colorectal cancer and cholangiocarcinoma.
Companies similar to Intera Oncology include Intio, InterCure, OncoSpherix and Advanced Chemotherapy Technologies.
Intera Oncology was founded in 2019.
Intera Oncology's headquarters is located in Wellesley, MA, US.
Intera Oncology's most recent funding round was for $413.5k (USD) in August 2021.
As of Aug 10, 2021, Intera Oncology has disclosed funding of $3.7M (USD). Undisclosed round amounts are excluded.
Intera Oncology has 37 employees as of Feb 5, 2024.
Advanced Chemotherapy Technologies
